Background-Treatment of acute rejection (AR) in heart transplantation relies on histopathological grading of endomyocardial biopsies according to International Society for Heart and Lung Transplantation guidelines. Intragraft gene expression profiling may be a way to complement histological evaluation. Methods and Results-Transcriptional profiling was performed on 26 endomyocardial biopsies, and expression patterns were compared with the 1990 International Society for Heart and Lung Transplantation AR grades. Importantly, transcriptional profiles from settings with an equivalent AR grade appeared the same. In addition, grade 0 profiles could not be distinguished from 1A profiles, and grade 3A profiles could not be distinguished from 3B profiles. Comparing the AR groupings (0ϩ1A, 1B, and 3Aϩ3B), 0ϩ1A showed more striking differences from 1B than from 3Aϩ3B. When these findings were extrapolated to the 2005 revised guidelines, the combination of 1A and 1B into a single category (1R) appears to have brought together endomyocardial biopsies with different underlying processes that are not evident from histological evaluation. Grade 1B was associated with upregulated immune response genes, as 1 categorical distinction from grade 1A. Although grade 1B was distinct from the clinically relevant AR grades 3A and 3B, all of these grades shared a small number of overlapping pathways consistent with common physiological underpinnings. Conclusion-The gene expression similarities and differences identified here in different AR settings have the potential to revise the clinical perspective on acute graft rejection, pending the results of larger studies. (Circulation. 2011;123:2236-2243 .) The online-only Data Supplement is available with this article at http://circ.ahajournals.org/cgi/content/full/CIRCULATIONAHA.109.913921/DC1.
D espite the success of heart transplantation as a therapy for end-stage heart failure, acute rejection (AR) continues to reduce long-term survival in transplant recipients. Acute rejection develops as a consequence of the recognition of nonself histocompatibility antigens and elaboration of an immune response against allogeneic heart muscle that leads to compromised cardiac function and graft loss. The histological evaluation of right ventricular endomyocardial biopsies (EMBs) is part of the current standard of care, and is based on the International Society for Heart and Lung Transplantation (ISHLT) guidelines, 1 as revised in 2005. 2 The greatest incidence of AR occurs in the first year post transplantation. 3 Patients who experience AR grades 3A, 3B, and 4 (revised grade 2R or 3R) within this time frame exhibit poor 5-year survival as well as an increased risk of cardiac allograft vasculopathy 4,5 despite intervention. Several studies have drawn attention to discordance between histological grade and graft function, particularly in settings where declining cardiac function and increasing mortality proceed independently of histological grade. 6, 7 These observations point to the need for greater understanding of underlying processes that may unveil alternative or complementary approaches for AR surveillance with the goal of accurate and early diagnosis. An accumulating body of evidence suggests that AR surveillance based on gene expression profiling in EMBs or peripheral blood cells may help improve clinical management. 8 -11 
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Intragraft gene expression studies have provided insight in the process of AR, [12] [13] [14] [15] [16] [17] [18] [19] although recent global intragraft gene expression profiling studies have not revealed a correlation with 2005 ISHLT AR grades. 11 Direct assessment of transcriptional profiles have proven valuable as an adjunct to tumor grading 20 as well as in kidney, [21] [22] [23] lung, 24 and liver 25 transplantation settings. In cardiac transplantation, such microarray analysis has suggested biomarkers for diagnosis of rejection and for distinguishing AR from infection. 26 We specifically investigated the relationship between tissuewide gene expression patterns and 1990 ISHLT AR grades to address key issues, including whether (1) intragraft gene expres-sion patterns, grouped by 1990 ISHLT grade, are consistent from patient to patient; (2) particular EMB-derived transcriptional profiles typify particular grades considering either the 1990 or 2005 guidelines; and (3) expression patterns provide insights into pathways or mechanisms contributing to AR.
Methods

Patients and Biopsies
Samples were selected from a cohort of 83 patients enrolled from 109 consecutive cardiac transplant recipients at Stanford University School of Medicine, Stanford, CA, between January 2002 and May 2004, who provided written informed consent approved by the institutional review board. The baseline immunosuppressive regimen consisted of induction with an interleukin-2 receptor antagonist (daclizumab), and a maintenance regimen of prednisone; cyclosporine A or tacrolimus; and mycophenolate mofetil (MMF) or sirolimus, as previously described. 27 All patients underwent routine AR surveillance, for which 4 to 6 EMBs were obtained from the right side of the interventricular septum. One, collected in RNAlater or optimal cutting temperature (snap frozen in liquid nitrogen and stored at Ϫ140°C), was used for microarray experiments, and the remainder were formalin-fixed, paraffin-embedded, sectioned, and histologically graded for AR by a cardiac pathologist according to the 1990 ISHLT criteria. 1 The most severe grading observed across multiple sections determined the AR grade. Because ISHLT guidelines were revised during the study course, 2 both the old and revised grades are shown in Table 1 . Patients receiving a score of Ն3A were treated with high-dose corticosteroids and/or antithymocyte-globulin.
In an effort to avoid confounding factors, we used the following stringent criteria to select EMBs for inclusion in this study: (1) absence of human leukocyte antigen (HLA) antibodies in patients preceding transplantation, (2) the EMB collected immediately preceding the EMB subjected to assay was free of signs of rejection (ie, grade 0), (3) absence of treatment for infections at time of and in the weeks before the EMB collection, (4) absence of hemodynamic compromise at the time of EMB collection, and (5) RNA of sufficient quality and quantity for use in microarray analysis. This resulted in a cohort of 23 patients providing 26 EMBs (grade 0, nϭ9; 1A, nϭ5; 1B, nϭ5; 3A, nϭ4; and 3B, nϭ3). Two patients provided Ͼ1 biopsy, each from a different grade and separated by a period that was free of rejection. As a result, only 1 biopsy per patient was included in comparative analyses (online-only Data Supplement Tables I through III) .
RNA Isolation, Amplification, and Hybridization
For total RNA extraction, EMBs were homogenized in 500 L TRIzol. After chloroform extraction, an RNeasy micro kit (Qiagen, Valencia, CA) was used on the aqueous phase. Messenger RNA was amplified and labeled with Cy5 using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies, Palo Alto, CA). The samples were mixed with equal amounts of amplified Cy-3-labeled human reference RNA (Stratagene, nr 740000, La Jolla, CA) and hybridized onto 22K oligomicroarrays (H1A-v2, Agilent Technologies) using the In Situ Hybridization Kit Plus (Agilent Technologies). All kits are used according to the manufacturer's instructions.
Data and Gene Filtering and Statistical Analysis
Data were collected using an Agilent Microarray Scanner, (model G2565AA) and processed, including Lowess normalization, using Agilent Feature Extraction Software (Agilent G2566AA), version A.6.1.1. Spot and gene filtering were performed using the standard settings for Agilent microarrays using the Stanford Microarray Database (http://genome-www5.stanford.edu/), averaging values for genes represented by multiple spots on the arrays. Data from nonuniform features, spots with intensities below background (defined by the feature extraction software), and outliers were excluded from the analysis. Arrays with 80% remaining data were used for analysis. Genes were median centered and significance analysis of microarrays (SAM) 28 multiclass and 2-class unpaired analyses were performed. Missing log 2 -based values were calculated using the K-nearest neighbor algorithm set to 10. A false discovery rate Ͻ1% was used for both the multiclass and 2-class analysis. Principal component analysis using the genes of the multiclass comparison was performed to display data set relatedness. Two-way hierarchical clustering of statistical significant genes was employed using the average linkage clustering algorithm in Cluster 29 and visualized in Java-Treeview. 30 The gene expression data are available through http://www.ncbi.nlm.nih.gov/geo, accession number GSE9377 and through http://genome-www5.stanford.edu/. Patient characteristics were compared using the Fisher exact for discrete and Mann-Whitney test for continuous variables.
Ingenuity Pathway Analysis (IPA, version 8.8) software (Mountain View, CA) was used to compute a molecular network based on published direct and indirect physical and functional interactions. Differentially expressed genes were entered into the Ingenuity Pathways Knowledge Base, and those recognized were further evaluated using their proprietary software package.
Results
Gene Expression Patterns in Relation to Acute Rejection Grading
We evaluated 26 EMBs from 23 heart transplant recipients, collected when signs of rejection or infection had been absent during the weeks preceding collection. After filtering the primary data, a set of 16 575 genes remained to explore relationships between expression patterns and histological AR grade. Multiclass SAM analysis followed by principal component analysis was performed to estimate relatedness of transcriptional profiles and AR grade. The first 2 principal components generally revealed 3 groupings ( Figure 1 ). International Society for Heart and Lung Transplantation grade 1B separated as a single group, with the other grades distributing into 2 additional groupings, 0ϩ1A and 3Aϩ3B. To further evaluate relationships and consistency of gene expression patterns across AR grades, we performed pairwise statistical comparisons. We found no significant differences between grade 0 and 1A biopsies. However, we identified differentially expressed genes when comparing either grade 0 or grade 1A to grade 1B EMBs ( Figure 1A through 1C) . Only a few genes were found to be differentially expressed comparing grade 1B to either 3A or 3B ( Figure 2D and 2E). Grade 3A and 3B samples from different patients were indistinguishable ( Figure 2F ). In addition, when a grade 3B sample collected at a different time from patient S ( Table 1) was included in the analysis, these AR groups remained indistinguishable (data not shown). These observations lead us to focus on comparing 3 groupings: 0ϩ1A, 1B, and 3Aϩ3B. There were no significant differences between groups (0ϩ1A; 1B, 3Aϩ3B) with respect to donor and recipient age and gender, HLA mismatch, ischemic time, and duration posttransplant ( Table 2) .
Most pronounced differences in transcriptional profiles were observed when comparing grouping 0ϩ1A versus grade 1B, with 458 statistically different genes, of which 343 were upregulated and 115 downregulated in 1B. Comparing groupings 0ϩ1A and 3Aϩ3B yielded 205 different genes, of which 136 were upregulated and 69 were downregulated in 3Aϩ3B. Comparing grade 1B with 3Aϩ3B revealed only 11 differences, all of which indicated downregulation in 3Aϩ3B relative to 1B. (Figure 2G through 2I ). Online-only Data Supplement Tables IV through VIII provide lists of significant different genes for each comparison. Overall, the intragraft gene expression patterns agreed with grading by histological assessment using the 1990 ISHLT system.
To visualize relationships between expression profiles and AR grades, we performed 2-way hierarchical cluster analysis with each set of differentially expressed genes. This distinguished and revealed striking consistency in 3 distinct AR groupings (Figure 3 ). Twenty-three out of 26 (88%) EMB profiles clustered according to the histological AR grade. Every grade 1B (5/5) and 13 out of 14 grade 0ϩ1A EMBs clustered together when the profiles of grade 0ϩ1A versus 1B were subjected to this analysis. The outlier 0ϩ1A EMB (No. 6) clustered with grade 1B ( Figure 3A ). Although the number of genes from the grade 1B versus 3Aϩ3B comparison was small, a cluster of the grade 1B versus 3Aϩ3B revealed that grade 1B expression patterns were highly related and independent of 3Aϩ3B. All but 1 grade 3Aϩ3B EMB clustered together ( Figure 3B ). Using the genes from the comparison 0ϩ1A versus 3Aϩ3B, all grade 0ϩ1A EMBs clustered, and 5 out of seven 3Aϩ3B EMBs clustered together. The 2 grade 3Aϩ3B samples that did not cluster with their corresponding grade seemed to form a separate cluster ( Figure 3C ), but further sample collection and analysis will be needed to determine any relevance of this small cluster.
The histological grades of the nonclustering EMBs were rereviewed by the pathologist (G.B.) without any revision of the initial histological grade. Intriguingly, the apparent relationship between transcriptional profiles and histological AR grade was not influenced by variable section-to-section histology (Table 1) , which raises a tantalizing possibility that transcriptional profiling may provide a more uniform less subjective read-out than histological evaluation.
Functional Pathway Analysis According to Acute Rejection Grading
To gain insights into the biological basis for differences in gene expression, we used Ingenuity Pathway Analysis (IPA) software. To identify functions associated with each of the AR grade groupings, functional analysis was performed using 434 out of 458 genes of the 0ϩ1A versus 1B comparison for which biological data were available. The top 5 significant biofunction categories of this analysis were inflammatory response; DNA replication, recombination, and repair; nucleic acid metabolism; small molecule biochemistry; and hematologic disease. A similar analysis of 197 out of 205 significant genes from the 0ϩ1A versus 3Aϩ3B comparison for which biological information was available yielded top biofunction categories of inflammatory response, cellular development, hematologic system development and function, hematopoiesis, and cellular function and development. The 1B versus 3Aϩ3B comparison contained too few genes to conduct a functional analysis.
To identify pathways that characterize the most dramatic differences, we used the canonical pathways tool of IPA on the genes from the 0ϩ1A versus 1B comparison. The top pathway identified was the antigen presentation pathway. Seven genes (B2M, CIITA, HLA-A, HLA-B, HLA-C, HLA-E, and TAP1) involved in classic and nonclassic MHC class I antigen presentation were upregulated in grade 1B. The second-most-significant pathway was related to antigen presentation, with allograft rejection pathway genes CD40 and granzyme B upregulated in addition to major Antigen presentation also predominated in the 0ϩ1A and 3Aϩ3B comparison, with upregulation of 6 genes (CD74, HLA-C, HLA-DPA1, HLA-DPB1, HLA-DRB5, and TAP1), representing both MHC class I and MHC class II. This differed from 1B rejections, where only MHC class I seems to be activated. Two other significant pathways in the 3Aϩ3B grouping were natural killer cell signaling and dendritic cell maturation, although neither one of these was significant in the grade 1B group. Despite the clinical relevance of the histological score, the allograft rejection pathway did not reach statistical significant in 3Aϩ3B profiles. Besides the MHC genes, no other genes in this pathway seem to have changed in the 3Aϩ3B grouping, according to the IPA knowledge base. Thus, although some similar processes and pathways may be present, a predominance of distinct processes characterize grade 1B, as compared with clinically relevant grades 3A or 3B AR. A summary of the IPA output for the comparisons 0ϩ1A versus 1B and 0ϩ1A versus 3A ϩ3B is provided in the online-only Data Supplement.
Discussion
Current methods of AR surveillance rely on histological evaluation of EMBs, an area that would benefit from approaches requiring fewer EMBs and providing more consistent sampleto-sample information. To explore a possible alternative approach for diagnosing AR using only a single EMB, this small study collected tissue-wide intragraft transcriptional profiles that generally correlated with histological AR grade on the basis of the 1990 ISHLT guidelines. We observed remarkable sampleto-sample consistency as highlighted by the statistical evaluation that grouped patients with similar grades of AR. The most surprising transcriptional differences were observed in grade 1B, compared to less severe 0ϩ1A. Despite the obvious need to apply these methods to larger sample sets, the genes associated with the different AR grades in this small study suggest that common tissue-wide pathways predominate in similar histological 1990 ISHLT AR grades and may require fewer EMBs to assign grades.
Our observations raise important questions about whether the 1990 1 or revised 2005 ISHLT guidelines 2 will ultimately bear a closer relationship to tissue-wide transcription profiles and provide the most clinically useful information. Whereas the 1990 grading system accommodated the groupings that resulted from our small set of gene expression profiles, the 2005 guidelines collapsed grades that showed distinct patterns and separated grades that showed similar profiles. Using an Affymetrix microarray approach, Mengel et.al did not detect any correlation between gene expression profiles and histological classification when applying the 2005 ISHLT grading system. Although they did not attempt to correlate their expression profiles with the 1990 AR grades, their results might have been influenced by the merger of rejection grades 1A and 1B in the revised guidelines, thereby averaging out the most striking gene expression differences observed here. 11 Widespread application of the 1990 guidelines led to (1) inconsistencies in grading among transplantation centers and (2) resulted in the recognition that grades 1 and 2 and some forms of 3A rarely (Ͻ25% of the time) progress, whereas grade 3B progresses and is associated with allograft failure. This provided an impetus to revise the grading system so that grades 1A, 1B, and 2 were combined into a single grade, 1R; 3A became 2R; and 3B together with 4 became 3R. Our data reveal strikingly different expression patterns between grade 1B compared with grades 0 and 1A, suggesting that grade 1B represents a distinct tissue state. The clinical innocence of grade 1B remains suspect among physicians, leading some transplant centers to modulate immunosuppression when diagnosing 1B. 31, 32 Combining 1A and 1B into 1R certainly undervalues any differences. Should the clinical relevance of grade 1B increase and larger transcriptional profiling studies confirm our results, the criteria employed for revised AR scoring might need to be revisited.
Grades 3A and 3B share a characteristic myocyte damage profile but differ histologically, with a multifocal inflammatory infiltration pattern characterizing grade 3A and a diffuse pattern characterizing 3B (Table 1) . Grade 3B exhibits more dramatic edema, hemorrhage, or vasculitis than 3A. However, gene expression patterns for grades 3A and 3B were indistinguishable. Although profiling reveals tissue-wide gene expression patterns, rigorous statistical evaluation tends to eliminate variable inflammatory markers from the analysis. 1, 2 Our failure to distinguish grade 3A from 3B by profiling could have resulted from insufficient sampling, individual variability, or dilution of relevant messenger RNA when assaying total tissue samples. The infiltrates in the grade 3B EMBs collected for evaluation in this study were diffuse, not widespread (Table 1) . Severe AR may have become less common because of improved immunosuppressive therapy, but will continue to benefit from histological evaluation. The fact that grades 3A (2R) and 3B (3R) were not distinguished by profiling a single EMB suggests that these more clinically relevant AR grades benefit from the direct histological review of multiple EMBs.
Overall, it was striking that we observed such a high level of consistency in tissue-wide transcriptional patterns on the basis of statistical analysis and clustering of EMBs into 3 groups, despite variability in histological grading of EMBs (Table 1) . Microarray profiling may smooth variability by sampling a greater percentage of tissue or by detecting qualities distinct from those observed under the microscope. Although interreader subjective variability in histological grading of rejections is recognized, 33 the small number of significant genes between grades 0ϩ1A and 3Aϩ3B groupings may have resulted from the use of a single EMB for microarray. The most severe reading drives diagnosis, even though this may be observed in fewer than half of evaluated EMBs. Further evaluation employing equivalent numbers of biopsies for both approaches, possibly by splitting each biopsy in 2, would be necessary to address this issue. Although pathway analysis and interpretation is difficult when based solely on messenger RNA expression because transcript levels are not always proportional to protein levels, we believe that changes in the expression of multiple genes in a pathway may implicate the pathway in the studied disease, and may provide new insights into underlying disease. An interesting observation is the fact that in 1B AR, inflammatory processes are ongoing, similar to 3A and 3B AR. However, nucleic acid metabolism, together with DNA repair and replication, seem to be more prevalent in 1B rejections, suggesting that both proliferation and repair processes are ongoing. Although MMF may cause these changes because of effects on purine and pyrimidine synthesis, 34, 35 the standard dose of MMF used here in all patients reduces the possibility that gene expression differences result from MMF treatment differences.
The most prominently changed pathway in both 1B and 3Aϩ3B AR was antigen presentation. Interestingly, all identified HLA molecules in grade 1B belonged to MHC class I, whereas in grade 3A and grade 3B rejections genes implicated in MHC class II were also upregulated. The absence of MHC class II in the 1B AR might result from the use of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors that can have an effect on MHC class II upregulation. Alternatively, grade 1B AR patterns may reflect antigen presentation to cytotoxic T-cells whereas 3A and 3B rejections may broader immune activity involving CD4ϩ and CD8ϩ T-lymphocytes.
In addition to the recognized limitations of this study, particularly the small sample size and use of a single EMB for profiling, histological review was by a single, albeit experienced, pathologist. Although the samples were reevaluated without any changes, we were unable to address potential reader-to-reader variability. This is a particular concern with grades 2, 3A, and 3B, where grade 2 had the lowest concordance rate among pathologists. For this reason we excluded grade 2, which has been ascribed to extend from quilty lesions and recategorizes often to 1A/1B or 3A/3B 33 from this study. Overall, we cannot estimate the extent to which quilty lesions contribute to the scores in our study.
Our reliance on a single EMB sample for microarray analysis means that sampling error and variability cannot be addressed directly. The stringent EMB selection criteria employed to avoid confounding factors means that the number of biopsies we analyzed was small. However, one of the most important of our findings was that histologically similar AR gradings grouped together, suggesting that the expression pattern in the single sample was influenced by the factors that drive histological grading. Thus, intragraft gene expression may turn out to be uniform and valuable as a way to determine physiological status of the transplanted heart.
We did not collect peripheral blood for comparison with EMBs by expression profiling. Comparing intragraft and peripheral blood gene expression patterns could have provided potentially complementary information. The predomi-nant reason for not initially planning to profile this compartment was the fact that changes in leukocyte subpopulations are a dominant contributor to gene expression differences that are observed, thereby limiting utility. Transplantation patients exhibit swings in complete blood count that would certainly complicate evaluation of whole-blood expression profiles. Nevertheless, peripheral blood profiling for AR has been used to discriminate between rejection grades 0 and Ն3A, and, more importantly, these studies have also suggested that grade 1B should be viewed as a distinct subset. 8, 36 Despite the limitations of our study, our data reveal gene expression patterns that are consistent with the histologically most severe grade in multiple sections of biopsies. This suggests that transcriptional profiling could complement histopathology in guiding treatment strategies. Additional larger studies with replicate and complementary tissues are needed to fully elucidate the gene expression signatures for each grade of rejection. Our observations provide a basis for further study of correlation with clinical outcome and novel directions for more detailed investigation of mechanisms underlying AR.
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CLINICAL PERSPECTIVE
Surveillance for acute cellular rejection after heart transplantation relies on histological evaluation of serial endomyocardial biopsies, an approach limited by sampling error and interobserver variations in the interpretation even when performed by the most experienced pathologist. This clinical area would benefit from technologies requiring fewer biopsies and more consistent sample-to-sample information. We have used intragraft transcriptional profiling to explore a possible alternative approach for diagnosing acute rejection. Using only 1 endomyocardial biopsy, our results show a consistent expression pattern between similar grades of acute rejection and distinctly different expression patterns between different rejection grades that was not influenced by variable section-to-section histology. Furthermore, the expression pattern distinguished grade 1B from all others and was thus more in accordance with the original International Society for Heart and Lung Transplantation grading scale (1990) than with the revised rejection grading system (2005 International Society for Heart and Lung Transplantation guidelines) that combines several rejection grades. These observations raise important clinical implications for acute cellular rejection surveillance: (1) transcriptional profiling may provide a more uniform read-out than histological evaluation, with less subjective section-to-section variability; (2) if confirmed in a larger sample set and a conclusive transcriptome identified for each rejection grade, transcriptional profiling can be an additional and complementary tool for diagnosing acute rejection, which can ultimately change the clinical practice to collecting fewer biopsies to diagnose rejection; and (3) the consistent expression pattern for grade 1B suggests that the International Society for Heart and Lung Transplantation grading system should be reevaluated to limit the combining of tissues with different underlying processes, taking into account new insights from advanced technologies.
